Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Ceribell (Nasdaq: CBLL) announced that Jane Chao, Ph.D., CEO and co‑founder will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 9:00 am PST / 12:00 pm EST.
A live and archived webcast of the presentation will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.
Positive
- None.
Negative
- None.
News Market Reaction – CBLL
On the day this news was published, CBLL gained 1.01%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves, with names like TMCI (+2.5%) and BFLY positive while others such as RXST and SMLR are negative. One peer, TMCI, also issued a J.P. Morgan Healthcare Conference participation release, suggesting event-related news rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Regulatory clearance | Positive | +5.0% | FDA 510(k) clearance for delirium monitoring solution extending Ceribell System. |
| Nov 24 | Regulatory clearance | Positive | +4.9% | FDA 510(k) clearance for Clarity algorithm across neonatal to adult seizures. |
| Nov 19 | Conference participation | Neutral | -0.1% | Announcement of presentation at Piper Sandler 37th Annual Healthcare Conference. |
| Nov 06 | Conference participation | Neutral | +3.6% | CFO fireside chat at Canaccord Genuity MedTech and Digital Health forum. |
| Nov 04 | Earnings update | Positive | -3.7% | Q3 2025 results with 31% revenue growth and raised full-year guidance. |
Recent FDA clearances have coincided with positive price reactions, while earnings with raised guidance saw a negative reaction, and conference appearances have had modest impact.
Over the last few months, Ceribell reported several notable milestones. On Nov 4, 2025, Q3 results showed revenue growth and higher guidance but the stock fell. Subsequent news on Nov 6 and Nov 19 highlighted participation in healthcare conferences, with modest share moves. Two FDA 510(k) clearances on Nov 24 and Dec 9, 2025 for seizure and delirium monitoring solutions were followed by positive reactions. Today’s J.P. Morgan conference participation aligns with this pattern of ongoing visibility alongside recent regulatory wins.
Regulatory & Risk Context
An effective S-3 shelf filed on Nov 4, 2025 allows Ceribell to offer up to $300,000,000 of various securities over time, providing flexibility to raise capital through future offerings as detailed in prospectus supplements.
Market Pulse Summary
This announcement centers on Ceribell’s participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, offering a platform to highlight recent FDA clearances and revenue growth. Historically, similar conference updates have had modest impact compared with regulatory milestones. Investors may watch for any disclosures tied to the event, while considering existing factors such as the $300,000,000 shelf registration and the company’s path toward narrowing net losses.
AI-generated analysis. Not financial advice.
SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 12, 2026, at 9:00 am Pacific Standard Time / 12:00 pm Eastern Standard Time.
Event: 44th Annual J.P. Morgan Healthcare Conference
Date: Monday, January 12, 2026
Time: 9:00 am PST / 12:00 pm EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Brian Price
Press@ceribell.com
FAQ
When will Ceribell (CBLL) present at the 44th Annual J.P. Morgan Healthcare Conference?
Who is presenting for Ceribell (CBLL) at the J.P. Morgan Healthcare Conference?
Where can investors watch the Ceribell (CBLL) presentation from January 12, 2026?
What time is Ceribell's (CBLL) webcast for viewers on the East Coast?
Will the Ceribell (CBLL) presentation at J.P. Morgan be archived for later viewing?
What topics is Ceribell (CBLL) expected to cover at the January 12, 2026 presentation?
